Mga Batayang Estadistika
| CIK | 1677940 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BeyondSpring Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
As filed with the Securities and Exchange Commission on August 13, 2025 As filed with the Securities and Exchange Commission on August 13, 2025 Registration No. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 BeyondSpring Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-38024 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 13, 2025 |
EXHIBIT 99.1 BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapies Med (Cell Press) Publication with MD Anderson Collaboration highlight |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38024 BeyondSpri |
|
| August 6, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| August 6, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 BeyondSpring Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-38024 Not Applicable (State or other jurisdiction of incorporation) (Commissio |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38024 BeyondSpr |
|
| May 12, 2025 |
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update EXHIBIT 99.1 BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapy SEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sa |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 BeyondSpring Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-38024 Not Applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 11, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 BeyondSpring Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-38024 Not Applicable (State or other jurisdiction of incorporation) (Commissi |
|
| April 11, 2025 |
Letter from Marcum LLP, dated April 11, 2025, addressed to the Securities and Exchange Commission Exhibit 16.1 April 11, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by BeyondSpring Inc. under Item 4.01 of its Form 8-K dated April 11, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of BeyondSpring Inc. contained therein. |
|
| March 27, 2025 |
Letter Agreement, dated as of August 7, 2024, between BeyondSpring U.S. and Lan Huang Exhibit 10.16 BEYONDSPRING PHARMACEUTICALS, INC. August 7, 2024 Lan Huang 4506 Delafield Ave, Bronx NY 10471 Re: Employment Terms Dear Lan: The purpose of this letter is to confirm certain changes that we expect to make with respect to the terms of your employment by BeyondSpring Pharmaceuticals, Inc. (“BeyondSpring”) in connection with the commencement of your separate and related employment by B |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 BeyondSpring Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-38024 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 27, 2025 |
EXHIBIT 99.1 BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. Docetaxel Plinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLC S |
|
| March 27, 2025 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2024, BeyondSpring (“we,” “us” or “our Company”) had the following series of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, par value $0.0001 per sh |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to To Commission File No. 001-38024 BeyondSpring In |
|
| March 27, 2025 |
Exhibit 19.1 BEYONDSPRING INC. POLICY ON INSIDER TRADING Adopted February 9, 2017 Updated January 19, 2018 Updated February 28, 2018 Updated April 27, 2018 This Insider Trading Policy describes the standards of BeyondSpring Inc. and its subsidiaries (the “Company”) on trading, and causing the trading of, the Company’s securities or securities of certain other publicly traded companies while in pos |
|
| March 27, 2025 |
List of Subsidiaries of BeyondSpring Inc. Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction of Incorporation BeyondSpring Pharmaceuticals, Inc. Delaware, United States BeyondSpring Ltd. British Virgin Islands BeyondSpring (HK) Limited Hong Kong Wanchun Biotechnology Limited British Virgin Islands Wanchun Biotechnology (Dalian) Ltd. China Dalian Wanchunbulin Pharmaceuticals Ltd. China SEED Therapeutics, Inc. British Virgin |
|
| February 25, 2025 |
Exhibit 10.4 FIRST AMENDMENT TO PURCHASE AGREEMENT This FIRST AMENDMENT TO PURCHASE AGREEMENT (this “Amendment”) is entered into as of this 17th day of February, 2025, by and between Winning View Investment Limited, a British Virgin Islands business company, and BeyondSpring Inc, a company formed under the laws of the Cayman Islands. W I T N E S S E T H: WHEREAS, the parties hereto have entered in |
|
| February 25, 2025 |
Unaudited Pro Forma Condensed Consolidated Financial Information Exhibit 99.1 Unaudited Pro Forma Condensed Consolidated Financial Information On January 24, 2025, Beyondspring Inc. (the “Company”) entered into a Preferred Share Purchase Agreement (each, an “Agreement” and collectively, the “Agreements”) with each of Winning View Investment Limited, a business company organized in the British Virgin Islands (“BVI”), FULL TECH CORPORATE DEVELOPMENT LIMITED, a bu |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2025 BeyondSpring Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-38024 Not Applicable (State or other jurisdiction of incorporation) (Comm |
|
| January 28, 2025 |
Exhibit 10.2 PREFERRED SHARE PURCHASE AGREEMENT BY AND AMONG BEYONDSPRING INC., AS THE SELLER, AND FULL TECH CORPORATE DEVELOPMENT LIMITED, AS THE PURCHASER Dated as of January 24, 2025 TABLE OF CONTENTS Page 1. DEFINITIONS. 1 1.1 Definitions 1 2. PURCHASE OF PURCHASED UNITS; CONSIDERATION; CLOSING. 1 2.1 Purchase of Purchased Shares. 1 2.2 Closing. 2 2.3 First Closing Deliveries. 2 2.4 Second Clo |
|
| January 28, 2025 |
Purchase Agreement, dated January 24, 2025, between BeyondSpring Inc. and Mapfil Investment Limited Exhibit 10.3 PREFERRED SHARE PURCHASE AGREEMENT BY AND AMONG BEYONDSPRING INC., AS THE SELLER, AND MAPFIL INVESTMENT LIMITED, AS THE PURCHASER Dated as of January 24, 2025 TABLE OF CONTENTS Page 1. DEFINITIONS. 1 1.1 Definitions 1 2. PURCHASE OF PURCHASED UNITS; CONSIDERATION; CLOSING. 1 2.1 Purchase of Purchased Shares. 1 2.2 Closing. 2 2.3 First Closing Deliveries. 2 2.4 Second Closing Deliverie |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 BeyondSpring Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-38024 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 28, 2025 |
Exhibit 10.1 PREFERRED SHARE PURCHASE AGREEMENT BY AND AMONG BEYONDSPRING INC., AS THE SELLER, AND WINNING VIEW INVESTMENT LIMITED, AS THE PURCHASER Dated as of January 24, 2025 TABLE OF CONTENTS Page 1. DEFINITIONS. 1 1.1 Definitions 1 2. PURCHASE OF PURCHASED UNITS; CONSIDERATION; CLOSING. 1 2.1 Purchase of Purchased Shares. 1 2.2 Closing. 2 2.3 First Closing Deliveries. 2 2.4 Second Closing Del |
|
| January 28, 2025 |
EXHIBIT 99.1 BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies FLORHAM PARK, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) - BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today anno |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 BeyondSpring Inc. (Exact name of registrant as specified in its charter) Cayman Islands 001-38024 Not Applicable (State or other jurisdiction of incorporation) (Commis |
|
| November 14, 2024 |
SC 13G/A 1 tm2427620d29sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G10830100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 (Address of principal executiv |
|
| August 6, 2024 |
Exhibit 99.1 SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai ◾■ The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegeneratio |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 (Address of principal executiv |
|
| July 10, 2024 |
100 Campus Drive, West Side, 4th Floor, Suite 410 BeyondSpring Inc. 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 July 10, 2024 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Dickerson Re: BeyondSpring Inc. Registration Statement on Form F-3, as amended (File No. 333-280153) Ladies and Gentlemen: Pursuant to Rule 461 under |
|
| July 2, 2024 |
As filed with the Securities and Exchange Commission on July 2, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 2, 2024 Registration No. |
|
| July 2, 2024 |
July 2, 2024 BY EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F St. |
|
| June 12, 2024 |
BeyondSpring Inc. Ordinary Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-257639 PROSPECTUS SUPPLEMENT (To Prospectus dated July 13, 2021) BeyondSpring Inc. 1,271,187 Ordinary Shares We are offering 1,271,187 of our ordinary shares to Dr. Quanqi Song pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with such investor. The offering price is |
|
| June 12, 2024 |
As filed with the Securities and Exchange Commission on June 12, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 12, 2024 Registration No. |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated June 12, 2024 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 (Address of principal executive offices |
|
| June 12, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (as may be amended, modified, or supplemented from time to time, this “Agreement”) is made and entered into as of June 12, 2024, by and between BeyondSpring Inc., an exempt company with limited liability organized under the laws of the Cayman Islands (the “Company”) and Quanqi Song (the “Purchaser”). WHEREAS, the Company |
|
| June 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) BEYONDSPRING INC. |
|
| April 29, 2024 |
Exhibit 4.6 Eighteenth Amendment to Consulting Agreement This Seventeenth Amendment ("Amendment") to Consulting Agreement is effective as of April 01st, 2024 (the “Effective Date”) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (“GKOL”), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an offi |
|
| April 29, 2024 |
Consent of Maples and Calder (Hong Kong) LLP Exhibit 15.3 Our ref FCT/715660-000001/26094303v1 Direct tel +852 3690 7513 Email [email protected] BeyondSpring Inc. 100 Campus Drive West Side 4th Floor, Suite 410 Florham Park New Jersey 07932 29 April, 2024 Dear Sirs BeyondSpring Inc. We have acted as legal advisers as to the laws of the Cayman Islands to BeyondSpring Inc., an exempted limited liability company incorporated in the Cayman |
|
| April 29, 2024 |
Consent of Jingtian & Gongcheng Exhibit 15.4 April 29, 2024 BeyondSpring Inc. (the “Company”) 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 The United States of America Ladies and Gentlemen: We have acted as legal advisors as to the laws of the People’s Republic of China to the Company in connection with the filing by the Company with the United States Securities and Exchange Commission of an a |
|
| April 29, 2024 |
Exhibit 12.1 Certification by Principal Executive and Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, certify that: 1. I have reviewed this annual report on Form 20-F of BeyondSpring Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the sta |
|
| April 29, 2024 |
Consent of Ernst & Young Hua Ming LLP Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-257639) of BeyondSpring Inc., (2) Registration Statement (Form S-8 No. 333-216639) pertaining to the 2017 Omnibus Incentive Plan of BeyondSpring Inc., and (3) Registration Statement (Form S-8 No. 33 |
|
| April 29, 2024 |
Clawback Policy of BeyondSpring Inc. Exhibit 97.1 BEYONDSPRING INC. CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of BeyondSpring Inc. (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date. 1. Definitions For |
|
| April 29, 2024 |
Letter Agreement, dated as of March 20, 2024, between BeyondSpring U.S. and Yingjuan (June) Lu Exhibit 4.28 March 20, 2024 Dear June(Yingjuan Lu), I am thrilled to share with you that, in recognition of your exceptional dedication, expertise, and contributions to BeyondSpring, you have been promoted to Chief Scientific Officer (CSO) which will be effective from April 1, 2024. This is a significant milestone in your career with us, marking the beginning of a new chapter filled with promise a |
|
| April 29, 2024 |
Exhibit 15.2 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT We consent to the incorporation by reference in the Registration Statements of BeyondSpring Inc. on Form F-3 (File No. 333-257639) and Form S-8 (File Nos. 333-216639 and 333-240082), of our report dated April 29, 2024, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect |
|
| April 29, 2024 |
Letter from Ernst & Young Hua Ming LLP to the Securities and Exchange Commission Exhibit 16.1 Letter from Ernst & Young Hua Ming LLP to the Securities and Exchange Commission April 29, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 16F of Form 20-F dated April 29, 2024 of BeyondSpring Inc. and are in agreement with the statements contained in the first to third paragraphs on page 168 therein. We have no basis to |
|
| April 29, 2024 |
Letter Agreement, dated as of October 11, 2023, between BeyondSpring U.S. and Lan Huang Exhibit 4.23 BEYONDSPRING PHARMACEUTICALS, INC. October 11, 2023 Lan Huang 4506 Delafield Ave, Bronx NY 10471 Re: Employment Terms Dear Lan: The purpose of this letter is to confirm certain changes that we expect to make with respect to the terms of your employment by BeyondSpring Pharmaceuticals, Inc. (“BeyondSpring”) in connection with the commencement of your separate and related employment by |
|
| April 29, 2024 |
Exhibit 4.5 Seventeenth Amendment to Consulting Agreement This Seventeenth Amendment ("Amendment") to Consulting Agreement is effective as of January 01st, 2024 (the “Effective Date”) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (“GKOL”), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an o |
|
| April 29, 2024 |
Exhibit 4.4 Sixteenth Amendment to Consulting Agreement This Sixteenth Amendment ("Amendment") to Consulting Agreement is effective as of July 01st, 2023 (the “Effective Date”) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (“GKOL”), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an office a |
|
| April 29, 2024 |
Letter Agreement, dated as of September 17, 2021, between BeyondSpring U.S. and Yingjuan (June) Lu Exhibit 4.27 Robert Azzara Vice President of Human Resources BeyondSpring Pharmaceuticals, Inc. 28 Liberty Street, 39th Floor New York, NY 10005 September 17, 2021 Re: Offer Letter Yingjuan Lu 833 Warrick St West Lafayette, IN 47906 Dear Yingjuan(June), BeyondSpring Pharmaceuticals, Inc. (“BeyondSpring” or the “Company”) is pleased to offer you a position at BeyondSpring. Please find below an over |
|
| April 29, 2024 |
Exhibit 13.1 Certification by Principal Executive and Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, Chief Executive Officer of BeyondSpring Inc. (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: ● the Company’s annual report on Form |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 29, 2024 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 2.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2023, BeyondSpring (“we,” “us” or “our Company”) had the following series of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, par value $0.0001 per sh |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 (Address of principal executive |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 (Address of principal execut |
|
| February 26, 2024 |
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements Exhibit 99.1 BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements FLORHAM PARK, N.J., February 26, 2024 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outco |
|
| February 14, 2024 |
BYSI / BeyondSpring Inc. / Ever Regal Group Ltd - SC 13G/A Passive Investment SC 13G/A 1 ef20021715sc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G10830100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing this Statement) Check |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 (Address of principal execut |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 (Address of principal executi |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 (Address of principal executi |
|
| January 10, 2024 |
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K Exhibit 99.1 BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K NEW YORK, January 10, 2024 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients wit |
|
| December 18, 2023 |
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements Exhibit 99.1 BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements NEW YORK, December 18, 2023 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high u |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by che |
|
| October 30, 2023 |
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement NEW YORK, October 30, 2023 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by che |
|
| October 4, 2023 |
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements Exhibit 99.1 BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements NEW YORK, October 4, 2023 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unm |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by c |
|
| September 15, 2023 |
September 15, 2023 BY EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F St. |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check m |
|
| April 18, 2023 |
Exhibit 4.5 Fifteenth Amendment to Consulting Agreement This Fifteenth Amendment ("Amendment") to Consulting Agreement is effective as of January 01st, 2023 (the “Effective Date”) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (“GKOL”), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an offic |
|
| April 18, 2023 |
6-K 1 brhc200515156k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal execut |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 18, 2023 |
EX-4.4 3 ex500853.htm EXHIBIT 4.4 Exhibit 4.4 Fourteenth Amendment to Consulting Agreement This Fourteenth Amendment ("Amendment") to Consulting Agreement is effective as of June 01, 2022 (the “Effective Date”) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (“GKOL”), and BeyondSpring Pharmaceuticals, Inc., a Dela |
|
| April 18, 2023 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 2.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2022, BeyondSpring (“we,” “us” or “our Company”) had the following series of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, par value $0.0001 per sh |
|
| April 18, 2023 |
Letter Agreement, dated as of March 23, 2023, between BeyondSpring U.S. and Lan Huang Exhibit 4.29 March 23, 2023 Lan Huang 4506 Delafield Ave, Bronx NY 10471 Re: Salary adjustment Dear Lan: Hope this letter finds you well. Per our discussion, this letter is to inform you about your salary adjustment. Following a careful assessment of our current financial situation and operations, we have approved your request for a salary reduction. Effective from April 1, 2023, your salary will |
|
| April 18, 2023 |
Separation Agreement, dated as of February 28, 2023, between BeyondSpring U.S. and Ramon W. Mohanlal Exhibit 4.28 Severance and Release Agreement This Severance and Release of Claims Agreement ("Agreement") is entered into by and between BeyondSpring Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 28 Liberty Street, New York, NY 10005 (the "Employer"), and Dr. Ramon Mohanlal, an individual (the "Employee") (collectively the “Parties” and each a “Party”) effec |
|
| April 18, 2023 |
Consent of Han Kun Law Offices Exhibit 15.3 April 18, 2023 BeyondSpring Inc. (the “Company”) 39th Floor 28 Liberty Street New York, New York 10005 The United States of America Ladies and Gentlemen: We have acted as legal advisors as to the laws of the People’s Republic of China to the Company in connection with the filing by the Company with the United States Securities and Exchange Commission of an annual report on Form 20-F f |
|
| April 18, 2023 |
Consent of Ernst & Young Hua Ming LLP Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-257639) of BeyondSpring Inc., (2) Registration Statement (Form S-8 No. 333-216639) pertaining to the 2017 Omnibus Incentive Plan of BeyondSpring Inc., and (3) Registration Statement (Form S-8 No. 33 |
|
| April 18, 2023 |
Consent of Maples and Calder (Hong Kong) LLP Exhibit 15.2 Our ref FCT/715660-000001/26094303v1 Direct tel +852 3690 7513 Email [email protected] BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 18 April 2023 Dear Sirs BeyondSpring Inc. We have acted as legal advisers as to the laws of the Cayman Islands to BeyondSpring Inc., an exempted limited liability company incorporated in the Cayman Islands (the “Company”), |
|
| April 18, 2023 |
Exhibit 13.1 Certification by Principal Executive and Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, Chief Executive Officer of BeyondSpring Inc. (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: ● the Company’s annual report on Form |
|
| April 18, 2023 |
Exhibit 12.1 Certification by Principal Executive and Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, certify that: 1. I have reviewed this annual report on Form 20-F of BeyondSpring Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the sta |
|
| April 7, 2023 |
BYSI / BeyondSpring Inc / Ever Regal Group Ltd - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G10830100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| February 14, 2023 |
BYSI / Beyondspring Inc / Ever Regal Group Ltd - SC 13G/A Passive Investment SC 13G/A 1 ny20007509x1s13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G10830100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing this Statement) Check |
|
| January 9, 2023 |
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules Exhibit 99.1 BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules NEW YORK, January 9, 2023 – BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on December 29, 2022, the Company received a written notification (the “Notificat |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by che |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| November 23, 2022 |
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements Exhibit 99.1 BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements NEW YORK, November 23, 2022 ? BeyondSpring Inc. (the ?Company? or ?BeyondSpring?) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on November 18, 2022, it received a written notification from The Nasdaq Stock Market LLC |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by chec |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| April 14, 2022 |
Consent of Ernst & Young Hua Ming LLP Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-257639) of BeyondSpring Inc., (2) Registration Statement (Form S-8 No. 333-216639) pertaining to the 2017 Omnibus Incentive Plan of BeyondSpring Inc., and (3) Registration Statement (Form S-8 No. 33 |
|
| April 14, 2022 |
Letter Agreement, dated as of January 13, 2022, between BeyondSpring U.S. and Ramon W. Mohanlal Exhibit 4.26 January 13, 2022 Ramon Mohanlal 219 west 81 street unit 6D New York, NY US 10024 Dear Ramon, We would like to thank you for your commitment to BeyondSpring. Your contributions to the organizations are valued, and we look forward to the new year and to working together to make plinabulin available to patients in need. We have had to make the difficult decision to prioritize the Company |
|
| April 14, 2022 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 2.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2021, BeyondSpring (?we,? ?us? or ?our Company?) had the following series of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, par value $0.0001 per sh |
|
| April 14, 2022 |
Exhibit 13.2 Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Elizabeth Czerepak, Chief Financial Officer of BeyondSpring Inc. (the ?Company?), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: ? the Company?s annual report on Form 20-F |
|
| April 14, 2022 |
Exhibit 4.28 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this ?Amendment?) is entered into on January 11, 2022 (the ?Effective Date?) by and between BeyondSpring Pharmaceuticals, Inc. (?Company?) and Elizabeth Czerepak (?Employee?) (collectively, the ?Parties?). WHEREAS, Employee and the Company entered into an employment agreement on September 11, |
|
| April 14, 2022 |
Exhibit 4.5 Thirteenth Amendment to Consulting Agreement This Thirteenth Amendment ("Amendment") to Consulting Agreement is effective as of January 01, 2022 (the ?Effective Date?) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (?GKOL?), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an offic |
|
| April 14, 2022 |
Consent of Maples and Calder (Hong Kong) LLP Exhibit 15.2 Our ref VSL/715660-000001/19218229v1 Direct tel +852 3690 7513 Email [email protected] BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 14 April 2022 Dear Sirs BeyondSpring Inc. We have acted as legal advisers as to the laws of the Cayman Islands to BeyondSpring Inc., an exempted limited liability company incorporated in the Cayman Islands (the ?Company?), |
|
| April 14, 2022 |
Letter Agreement, dated as of January 13, 2022, between BeyondSpring U.S. and Elizabeth Czerepak Exhibit 4.29 January 13, 2022 Elizabeth Czerepak 3 Rosemaries Ln East Hampton, NY US 11937 Dear Elizabeth, We would like to thank you for your commitment to BeyondSpring. Your contributions to the organizations are valued, and we look forward to the new year and to working together to make plinabulin available to patients in need. We have had to make the difficult decision to prioritize the Compan |
|
| April 14, 2022 |
Exhibit 4.9 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this ?Second Amendment?) is entered into on January 11, 2022 (the ?Effective Date?) by and between BeyondSpring Pharmaceuticals, Inc. (?Company?) and Dr. Gordon Schooley (?Employee?) (collectively, the ?Parties?). WHEREAS, Employee and the Company entered into an employment agreement on June 16, 201 |
|
| April 14, 2022 |
Consent of Han Kun Law Offices Exhibit 15.3 April 14, 2022 BeyondSpring Inc. (the ?Company?) 39th Floor 28 Liberty Street New York, New York 10005 The United States of America Ladies and Gentlemen: We have acted as legal advisors as to the laws of the People?s Republic of China to the Company in connection with the filing by the Company with the United States Securities and Exchange Commission of an annual report on Form 20-F f |
|
| April 14, 2022 |
Consulting Agreement, dated as of November 6, 2021, between BeyondSpring Inc. and Brendan Delaney Exhibit 4.31 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (?Agreement?) dated Nov. 6, 2021 (the ?Effective Date?) is made between BeyondSpring Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, having its principal place of business at 28 Liberty Street, 39th Floor, New York, NY 10005 (the ?Company?) and Brendan Delaney, having a principal place of business at 475 Park Av |
|
| April 14, 2022 |
Exhibit 4.7 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this ?Second Amendment?) is entered into on January 11, 2022 (the ?Effective Date?) by and between BeyondSpring Pharmaceuticals, Inc. (?Company?) and Dr. Lan Huang (?Employee?) (collectively, the ?Parties?). WHEREAS, Employee and the Company entered into an employment agreement on April 1, 2016 (the |
|
| April 14, 2022 |
Exhibit 4.8 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this "Second Amendment") is entered into on January 11, 2022 (the "Effective Date") by and between BeyondSpring Pharmaceuticals, Inc. ("Company") and Dr. Ramon Mohanlal ("Employee") (collectively, the "Parties"). WHEREAS, Employee and the Company entered into an employment agreement on April 1, 2016 |
|
| April 14, 2022 |
Exhibit 13.1 Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, Chief Executive Officer of BeyondSpring Inc. (the ?Company?), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: ? the Company?s annual report on Form 20-F for the y |
|
| April 14, 2022 |
Exhibit 4.24 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (this ?Amendment?), dated this 12th day of October, 2021 (the "Effective Date"), is entered into by and between BeyondSpring Pharmaceuticals, Inc. (the ?Company?) and Mr. Richard Daly ( ?Employee?). RECITALS WHEREAS, the Company and Employee are parties to that Employment Agreement, dated as of June 8 |
|
| April 14, 2022 |
Separation Agreement, dated as of January 27, 2022, between BeyondSpring U.S. and Richard Daly Exhibit 4.32 Separation and Release Agreement This Separation and Release of Claims Agreement ("Agreement") is entered into by and between BeyondSpring Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 28 Liberty Street, New York, NY 10005 (the "Employer"), and Richard Daly, an Illinois resident working for Employer in New York (the "Employee") (collectively the |
|
| April 14, 2022 |
Exhibit 12.2 Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Elizabeth Czerepak, certify that: 1. I have reviewed this annual report on Form 20-F of BeyondSpring Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statemen |
|
| April 14, 2022 |
Exhibit 12.1 Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, certify that: 1. I have reviewed this annual report on Form 20-F of BeyondSpring Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 14, 2022 |
Letter Agreement, dated as of January 13, 2022, between BeyondSpring U.S. and Gordon Schooley Exhibit 4.27 January 13, 2022 Gordon Schooley 11926 Port Labelle Dr Las Vegas, NV US 89141 Dear Gordon, We would like to thank you for your commitment to BeyondSpring. Your contributions to the organizations are valued, and we look forward to the new year and to working together to make plinabulin available to patients in need. We have had to make the difficult decision to prioritize the Company?s |
|
| April 14, 2022 |
Letter Agreement, dated as of January 13, 2022, between BeyondSpring U.S. and Lan Huang Exhibit 4.25 January 13, 2022 Lan Huang 4506 Delafield Ave Bronx, NY US 10471 Dear Lan, We would like to thank you for your commitment to BeyondSpring. Your contributions to the organizations are valued, and we look forward to the new year and to working together to make plinabulin available to patients in need. We have had to make the difficult decision to prioritize the Company?s goals and objec |
|
| February 14, 2022 |
BYSI / Beyondspring Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Beyondspring Inc (Name of Issuer) Common Stock (Title of Class of Securities) G10830100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 14, 2022 |
BYSI / Beyondspring Inc / Shenzhen Sangel Capital Management Ltd Co - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 14, 2022 |
BYSI / Beyondspring Inc / Decheng Capital Management III (Cayman), LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BeyondSpring Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) G10830100 (CUSIP Number) Laura Tse 3000 Sand Hill Road, Building 2, Suite 110 Menlo Park, CA 94025, USA 650-233-0688 (Name, Address and Telephone Number of P |
|
| February 11, 2022 |
BYSI / Beyondspring Inc / Ever Regal Group Ltd - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G10830100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule |
|
| January 11, 2022 |
BeyondSpring Announces Organizational Streamlining Exhibit 99.1 BeyondSpring Announces Organizational Streamlining - Resources to be Focused on Highest Value Business Activities - 35% Reduction in Workforce in the U.S. Implemented to Preserve Long-Term Sustainability NEW YORK, January 11, 2022 ? BeyondSpring Pharmaceuticals (the ?Company? or ?BeyondSpring?) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therap |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File No. 001-38024 BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of Principal Executive Offices) Indicate by check mark whether the regi |
|
| December 30, 2021 |
Exhibit 99.1 BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update - Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. Docetaxel alone - IO combination advancement to Phase 2: pli |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 September 30, 2021-12-31 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executi |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| December 1, 2021 |
Exhibit 99.1 CONFIDENTIAL DRAFT BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN) NEW YORK, December 1, 2021 ? BeyondSpring Pharmaceuticals (the ?Company? or ?BeyondSpring?) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today an |
|
| November 10, 2021 |
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors EX-99.1 2 brhc10030689ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors NEW YORK, November 10, 2021 — BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage biopharmaceutical company focused on the development of innovative cancer therapeutics, today announced the appointment of Mark Santos, R |
|
| November 10, 2021 |
6-K 1 brhc100306896k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal exe |
|
| September 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by c |
|
| September 21, 2021 |
Exhibit 99.1 BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology (ESMO) 2021 Congress ? Study met the primary endpoint showing statistically significant improvement in overall survival (OS) for |
|
| September 10, 2021 |
Exhibit 99.1 BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update - Management to host a call today at 8:00 am ET NEW YORK, Sept. 10, 2021 ? BeyondSpring Inc. (the ?Company? or ?BeyondSpring?) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced its financial results for the second quar |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2021 June 30, 2021 -12-31 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive |
|
| August 26, 2021 |
Exhibit 99.1 BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China ? Wanchunbulin, BeyondSpring?s 58%-owned subsidiary in China, to partner with Hengrui, the leader in oncology product R&D and commercialization in China, for the exclusive commercial and co-development rights for plinabulin in Greater Chi |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by chec |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by chec |
|
| August 5, 2021 |
Exhibit 99.1 Plinabulin DUBLIN-3 NSCLC Topline Data August 5 2021 | NASDAQ: BYSI Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale |
|
| August 4, 2021 |
Exhibit 99.1 BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type ? Study met primary endpoint showing statistically significant improvement in overall survival (OS) for the combination vs. docetaxel. ? Study met key secondary endpoi |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by chec |
|
| July 14, 2021 |
Exhibit 99.1 BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney NEW YORK, July 14, 2021 - BeyondSpring (the ?Company? or ?BeyondSpring?) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Directors, effective immediate |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| July 9, 2021 |
BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 July 9, 2021 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: BeyondSpring Inc. Registration Statement on Form F-3 (File No. 333-257639) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Beyon |
|
| July 2, 2021 |
As filed with the Securities and Exchange Commission on July 2, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 2, 2021 Registration No. |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| June 16, 2021 |
EX-99.1 2 brhc10025730ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update - NDA Filed by U.S. Food and Drug Administration(FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA. - Highlighted PROTECTIVE-2 Phase 3 data at two scien |
|
| April 30, 2021 |
Exhibit 12.2 Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Elizabeth Czerepak, certify that: 1. I have reviewed this annual report on Form 20-F of BeyondSpring Inc. (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statemen |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2021 |
Exhibit 4.32 EMPLOYMENT AGREEMENT This Employment Agreement ("Agreement") is entered into this on September 11, 2020 (the "Effective Date") by and between BeyondSpring Pharmaceuticals, Inc. ("Company") and Elizabeth Czerepak ("Employee") (collectively, the "Parties"). WHEREAS, Employee and Company desire to enter into an agreement in which Employee will be an employee of the Company; WHEREAS, the |
|
| April 30, 2021 |
Amendment to the BeyondSpring Inc. 2017 Omnibus Incentive Plan, effective September 18, 2020 Exhibit 4.14 BEYONDSPRING INC. 2017 OMNIBUS INCENTIVE PLAN (as Amended and Restated as of September 18, 2020) Section 1. Purpose of Plan. The name of the Plan is the BeyondSpring Inc. 2017 Omnibus Incentive Plan (the ?Plan?), as amended and restated as of September 18, 2020. The purposes of the Plan are to provide an additional incentive to selected officers, employees, non-employee directors, ind |
|
| April 30, 2021 |
Exhibit 13.1 Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, Chief Executive Officer of BeyondSpring Inc. (the ?Company?), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: ? the Company?s annual report on Form 20-F for the y |
|
| April 30, 2021 |
Exhibit 15.2 Our ref VSL/715660-000001/16368950v1 Direct tel +852 3690 7513 Email [email protected] BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 April 30, 2021 Dear Sirs BeyondSpring Inc. We have acted as legal advisers as to the laws of the Cayman Islands to BeyondSpring Inc., an exempted limited liability company incorporated in the Cayman Islands (the ?Company?), |
|
| April 30, 2021 |
Exhibit 4.6 Eleventh Amendment to Consulting Agreement This Eleventh Amendment (?Amendment?) to Consulting Agreement is effective as of January 1, 2021 (the ?Effective Date?) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (?GKOL?), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an office at |
|
| April 30, 2021 |
Consulting Agreement, dated as of January 26, 2021, between BeyondSpring Inc. and Jeffrey Vacirca Exhibit 4.33 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (?Agreement?) dated January 26, 2021 (the ?Effective Date?) is made between BeyondSpring Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, having its principal place of business at 28 Liberty Street, 39th Floor, New York, NY 10005 (the ?Company?) and Jeffrey Vacirca, having a principal place of business at 460 Kin |
|
| April 30, 2021 |
Exhibit 13.2 Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Elizabeth Czerepak, Chief Financial Officer of BeyondSpring Inc. (the ?Company?), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: ? the Company?s annual report on Form 20-F |
|
| April 30, 2021 |
Exhibit 4.7 Twelfth Amendment to Consulting Agreement This Twelfth Amendment (?Amendment?) to Consulting Agreement is effective as of March 15th, 2021 (the ?Effective Date?) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (?GKOL?), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an office at 2 |
|
| April 30, 2021 |
Exhibit 15.3 April 30, 2021 BeyondSpring Inc. (the "Company") 39th Floor 28 Liberty Street New York, New York 10005 The United States of America Ladies and Gentlemen: We have acted as legal advisors as to the laws of the People's Republic of China to the Company in connection with the filing by the Company with the United States Securities and Exchange Commission of an annual report on Form 20-F f |
|
| April 30, 2021 |
Ninth Amendment to Consulting Agreement Exhibit 4.4 Ninth Amendment to Consulting Agreement This Ninth Amendment (?Amendment?) to Consulting Agreement is effective as of August 1, 2020 (the ?Effective Date?) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (?GKOL?), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an office at 28 Libe |
|
| April 30, 2021 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No. 333-224437) of BeyondSpring Inc., (2) Registration Statement (Form F-3 No. 333-249816) of BeyondSpring Inc., (3) Registration Statement (Form S-8 No. 333-216639) pertaining to the 2017 Omnibus Incentive |
|
| April 30, 2021 |
Exhibit 12.1 Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, certify that: 1. I have reviewed this annual report on Form 20-F of BeyondSpring Inc. (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 30, 2021 |
Tenth Amendment to Consulting Agreement Exhibit 4.5 Tenth Amendment to Consulting Agreement This Tenth Amendment (?Amendment?) to Consulting Agreement is effective as of November 1, 2020 (the ?Effective Date?) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (?GKOL?), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corporation, with an office at 28 Li |
|
| April 30, 2021 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2020, BeyondSpring (?we,? ?us? or ?our Company?) had the following series of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, par value $0.0001 per sh |
|
| April 1, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by chec |
|
| April 1, 2021 |
Exhibit 99.1 BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN) - Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alone - Pl |
|
| March 29, 2021 |
Current Report of Foreign Issuer - 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| March 19, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 19, 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check mark whether |
|
| March 16, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by chec |
|
| February 16, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G10830100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule |
|
| February 9, 2021 |
EX-99.3 4 nc10019837x1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 |
|
| February 9, 2021 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 nc10019837x16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2021 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of princip |
|
| February 9, 2021 |
Exhibit 99.2 BEYONDSPRING INC. (THE “COMPANY”) NOTICE OF EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS OF THE COMPANY IMPORTANT Terms not otherwise defined in this notice shall have the meanings given to such terms in the Amended and Restated Memorandum and Articles of Association of the Company adopted on 24 February 2017 and effective immediately prior to the completion of the Company’s init |
|
| February 9, 2021 |
BEYONDSPRING INC. PROXY STATEMENT Exhibit 99.1 BEYONDSPRING INC. PROXY STATEMENT General The board of directors of BeyondSpring Inc. (the “Company,” “we,” “us” or “our”) is soliciting proxies for the Extraordinary General Meeting of Shareholders (the “EGM”) of the Company to be held on March 15, 2021 at 9 a.m., Eastern Standard Time, at 28 Liberty Street, 39th Floor, New York, NY 10005. In light of COVID-19 concerns, the EGM wil |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Beyondspring Inc (Name of Issuer) Common Stock (Title of Class of Securities) G10830100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| December 18, 2020 |
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors Exhibit 99.1 BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors NEW YORK – December 17, 2020 – BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as i |
|
| December 18, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by c |
|
| December 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, $0.0001 par value per share (Title of Class of Securities) G10830100 (CUSIP Number) Decheng Capital China Life Sciences USD Fund II, L.P. Decheng Capital China Life Sciences USD Fund III, L.P. Decheng C |
|
| November 23, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by c |
|
| November 23, 2020 |
BeyondSpring Inc. 7,500,000 Ordinary Shares (Par Value $0.0001 Per Share) UNDERWRITING AGREEMENT Exhibit 1.1 BeyondSpring Inc. 7,500,000 Ordinary Shares (Par Value $0.0001 Per Share) UNDERWRITING AGREEMENT November 18, 2020 BOFA SECURITIES, INC. JEFFERIES LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters c/o BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o EVERCORE GROUP L.L.C. 55 East 52nd |
|
| November 19, 2020 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-249816 PROSPECTUS SUPPLEMENT (To Prospectus dated November 12, 2020) 7,500,000 Ordinary Shares BeyondSpring Inc. We are offering 7,500,000 ordinary shares with an aggregate offering price of $75,000,000. Our ordinary shares are listed on the Nasdaq Capital Market under the symbol “BYSI.” The last reported sales pri |
|
| November 17, 2020 |
Subject to Completion Preliminary Prospectus Supplement dated November 17, 2020 TABLE OF CONTENTS The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| November 17, 2020 |
BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates Exhibit 99.1 BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates - Announced SEED Therapeutics Inc.(“SEED”)’s collaboration with Eli Lilly and Company(“Lilly”) NEW YORK, November 17, 2020 – BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today anno |
|
| November 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| November 16, 2020 |
Exhibit 99.1 BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia • Study met primary endpoint showing statistically significant improvement in rate of prevention of Grade 4 neutropenia in Cycle 1, p=0.0015 • Study met statistically significant improvemen |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated November 13, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check mar |
|
| November 13, 2020 |
Exhibit 99.1 BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly - Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines - NEW YORK – November 13, 2020 – Seed Therapeutics (“the Company”), a global research company and subsidiary of BeyondSpring focused on discovering and dev |
|
| November 10, 2020 |
BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 November 10, 2020 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Dave Gessert Re: BeyondSpring Inc. Registration Statement on Form F-3 (File No. 333-249816) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended |
|
| November 3, 2020 |
As filed with the Securities and Exchange Commission on November 3, 2020 Registration No. |
|
| September 22, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Dated September 22, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check ma |
|
| September 22, 2020 |
Exhibit 99.1 BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer - New Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO - NEW YORK, N.Y. – September 22, 2020 – Following its recent receipt of two Breakthrough Therapy Designations in both the U.S. and China for Plinabulin in the chemotherapy-induced neutropenia (CIN) indication, Beyon |
|
| September 3, 2020 |
Exhibit 99.1 BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates - Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin’s Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta Alone- - Completed PROTECTIVE-2 Phase 3 Enrollment and On Track to Report Final Results in Q4 2020 / Expect t |
|
| September 3, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 30, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| August 19, 2020 |
Exhibit 99.1 BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors Gilead Acquired Forty Seven in March 2020 for $4.9 Billion NEW YORK – August 18, 2020 – BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer ther |
|
| August 19, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by che |
|
| July 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, $0.0001 par value per share (Title of Class of Securities) G10830100 (CUSIP Number) Decheng Capital China Life Sciences USD Fund II, L.P. Decheng Capital China Life Sciences USD Fund III, L.P. Ugland Hou |
|
| July 24, 2020 |
Exhibit 99.3 [name] [date] RE: BeyondSpring Inc. Director Agreement Dear [name], I am writing to you on behalf of the board of directors of BeyondSpring Inc. (the “Company”) to confirm arrangements with regard to the terms of your appointment to office as a director of the Company from the date of this director agreement (this “Letter”). 1. Definitions For the purposes of this Letter, the followin |
|
| July 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BeyondSpring Inc. (Exact name of registrant as specified in charter) Cayman Islands Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) BeyondSpring Inc. 10005 28 Liberty Street, 39th Floor (Zip Code) |
|
| July 24, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| July 24, 2020 |
Amendment to the BeyondSpring Inc. 2017 Omnibus Incentive Plan EX-10.2 3 brhc10011607ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 Amendment to the BeyondSpring Inc. 2017 Omnibus Incentive Plan THIS AMENDMENT (this “Amendment”) is made as of July 24, 2020, to the BeyondSpring Inc. Omnibus Incentive Plan, as amended from time to time (the “2017 Incentive Plan”). Any capitalized terms used and not defined herein shall have the meanings set forth in the 2017 Incentive Pl |
|
| July 24, 2020 |
Exhibit 99.2 [name] [date], 2020 RE: First Amendment to BeyondSpring Inc. Director Agreement Dear [name], Reference is made to that certain director agreement, dated as of [], by and between BeyondSpring Inc. (the “Company”) and you (the “Director Agreement”). The Company desires to amend the Director Agreement, as provided herein in this letter amendment (this “Amendment”), effective as of July 1 |
|
| July 24, 2020 |
Amendment to the BeyondSpring Inc. 2017 Omnibus Incentive Plan Exhibit 99.1 Amendment to the BeyondSpring Inc. 2017 Omnibus Incentive Plan THIS AMENDMENT (this "Amendment") is made as of July 24, 2020, to the BeyondSpring Inc. Omnibus Incentive Plan, as amended from time to time (the "2017 Incentive Plan"). Any capitalized terms used and not defined herein shall have the meanings set forth in the 2017 Incentive Plan. WHEREAS, pursuant to Section 15 of the 201 |
|
| June 23, 2020 |
BeyondSpring Inc. 1,930,000 Ordinary Shares (Par Value $0.0001 Per Share) UNDERWRITING AGREEMENT Exhibit 1.1 BeyondSpring Inc. 1,930,000 Ordinary Shares (Par Value $0.0001 Per Share) UNDERWRITING AGREEMENT June 18, 2020 JEFFERIES LLC WILLIAM BLAIR & COMPANY, L.L.C. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o WILLIAM BLAIR & COMPANY, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: Introductory. |
|
| June 23, 2020 |
Exhibit 10.1 Execution Version SHARE SUBSCRIPTION AGREEMENT This SHARE SUBSCRIPTION AGREEMENT (this “Agreement”) is entered into as of June 18, 2020, by and among BeyondSpring Inc., a Cayman Islands company (the “Company”), Decheng Capital China Life Sciences USD Fund II, L.P., a Cayman Islands exempted limited partnership, and Decheng Capital China Life Sciences USD Fund III, L.P., a Cayman Islan |
|
| June 23, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| June 19, 2020 |
1,930,000 Ordinary Shares BeyondSpring Inc. TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-234193 PROSPECTUS SUPPLEMENT (To Prospectus dated October 21, 2019) 1,930,000 Ordinary Shares BeyondSpring Inc. We are offering 1,930,000 ordinary shares with an aggregate offering price of $25,090,000. Our ordinary shares are listed on the Nasdaq Capital Market under the symbol “BYSI.” The last reported sales pric |
|
| June 18, 2020 |
Subject to Completion Preliminary Prospectus Supplement dated June 18, 2020 TABLE OF CONTENTS The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by check |
|
| June 15, 2020 |
Exhibit 99.1 BeyondSpring Announces Positive Topline Interim Results from PROTECTIVE-2 (Study 106) Phase 3 Trial Evaluating Superiority of Plinabulin in Combination with Neulasta for Chemotherapy-Induced Neutropenia Prevention -Met Primary Endpoint of Rate of Severe (Grade 4) Neutropenia Prevention in First Chemotherapy Cycle (Cycle 1) (p<0.01)- -Met Key Secondary Endpoint of Duration of Severe Ne |
|
| June 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by chec |
|
| June 11, 2020 |
Exhibit 99.1 BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Update - PROTECTIVE-2 (Study 106) Phase 3 Interim Analysis This Month to Evaluate Superiority in CIN - - PROTECTIVE-2 Phase 2 Shows Positive Results in Chemotherapy Optimization with Potentially Better Clinical Outcomes - - DUBLIN-3 (Study 103 Phase 3) Second Interim Analysis for NSCLC Received DSMB’s Recommenda |
|
| April 30, 2020 |
Exhibit 4.22 Lan Huang, Ph.D. Chief Executive Officer BeyondSpring Pharmaceuticals, Inc. 28 Liberty Street, 39th Floor New York, NY 10005 Tel: 646.305.6387 January 1, 2020 RE: ANNUAL SALARY RAISE Lan Huang Dear Lan, We are pleased to offer you an increase in your annual base salary from $300,000.00 to $520,000.00. In addition, we are increasing your annual bonus opportunity from 30% of annual sala |
|
| April 30, 2020 |
Exhibit 12.2 Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Edward Dongheng Liu, certify that: 1. I have reviewed this annual report on Form 20-F of BeyondSpring Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the stateme |
|
| April 30, 2020 |
Exhibit 13.2 Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Edward Dongheng Liu, Chief Financial Officer of BeyondSpring Inc. (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: • the Company’s annual report on Form 20-F |
|
| April 30, 2020 |
Exhibit 4.25 Lan Huang, Ph.D. Chief Executive Officer BeyondSpring Pharmaceuticals, Inc. 28 Liberty Street, 39th Floor New York, NY 10005 Tel: 646.305.6387 January 1, 2020 RE: ANNUAL SALARY RAISE Gordon Schooley Dear Gordon, We are pleased to offer you an increase in your annual base salary from $250,000.00 to $300,000.00. In addition, we are increasing your annual bonus opportunity from 30% of an |
|
| April 30, 2020 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-216639) pertaining to the 2017 Omnibus Incentive Plan of BeyondSpring Inc. of our report dated April 30, 2020, with respect to the consolidated financial statements of BeyondSpring Inc., included in this Annual Report (Form 20-F) for the |
|
| April 30, 2020 |
Exhibit 4.24 Lan Huang, Ph.D. Chief Executive Officer BeyondSpring Pharmaceuticals, Inc. 28 Liberty Street, 39th Floor New York, NY 10005 Tel: 646.305.6387 December 9, 2019 RE: ANNUAL SALARY RAISE Ramon W. Mohanlal Dear Ramon, We are pleased to offer you an increase in your annual base salary from $300,000.00 to $430,000.00. In addition, we are increasing your annual bonus opportunity from 30% of |
|
| April 30, 2020 |
Exhibit 15.2 Our ref VSL/715660-000001/16368950v1 Direct tel +852 3690 7513 Email [email protected] BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 30 April 2020 Dear Sirs and/or Madams BeyondSpring Inc. We have acted as legal advisers as to the laws of the Cayman Islands to BeyondSpring Inc., an exempted limited liability company incorporated in the Cayman Islands (th |
|
| April 30, 2020 |
Exhibit 4.20 AMENDMENT TO EMPLOYMENT AGREEMENT The Employment Agreement by and between BeyondSpring Pharmaceuticals, Inc. (the “Company”) and Richard Daly (the “Employee”) dated as of June 8, 2018 (the “Agreement”) is hereby amended , effective as of September 24, 2019, as follows: 1. The final sentence of Section 3.a. of the Agreement is hereby deleted in its entirety and replaced with the follow |
|
| April 30, 2020 |
Exhibit 4.21 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to Employment Agreement (this “Amendment”), dated this12/26/19, is entered into by and between BeyondSpring Pharmaceuticals, Inc. (the “Company”) and Mr. Richard Daly (“Employee”). RECITALS WHEREAS, the Company and Employee are parties to that Employment Agreement, dated as of June 8, 2018, as amended by that Amendment, da |
|
| April 30, 2020 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 4.15 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the "Agreement") is entered into this January I, 2020 (the "Effective Date"), by and between BeyondSpring Pharmaceuticals, Inc. (the "Company") and Mr. James Tonra ("Employee") (collectively, the "Parties"). WHEREAS, the Company and Employee are parties to the certain Employment Agreement, dated |
|
| April 30, 2020 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2019, BeyondSpring (“we,” “us” or “our Company”) had the following series of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, par value $0.0001 per sh |
|
| April 30, 2020 |
Exhibit 12.1 Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, certify that: 1. I have reviewed this annual report on Form 20-F of BeyondSpring Inc. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 30, 2020 |
Exhibit 13.1 Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Lan Huang, Chief Executive Officer of BeyondSpring Inc. (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: • the Company’s annual report on Form 20-F for the y |
|
| April 30, 2020 |
9/F, Office Tower C1, Oriental Plaza, 1 East Chang An Ave., Dongcheng District Exhibit 15.3 9/F, Office Tower C1, Oriental Plaza, 1 East Chang An Ave., Dongcheng District Beijing 100738, PRC Tel: +86 10 8525 5500 Fax: +86 10 8525 5511 / 8525 5522 Beijing • Shanghai • Shenzhen • Hong Kong www.hankunlaw.com April 30, 2020 To: BeyondSpring Inc. (the “Company”) 28 Liberty Street, 39th Floor New York, New York 10005 Ladies and Gentlemen, We have acted as legal advisors as to the |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2020 |
Eighth Amendment to Consulting Agreement EX-4.3 3 ex43.htm EXHIBIT 4.3 Exhibit 4.3 Eighth Amendment to Consulting Agreement This Eighth Amendment (“Amendment”) to Consulting Agreement is effective as of January 1, 2020 (the “Effective Date”) and is entered into by and between GKOL, Inc., a California corporation, with an office at 210 Montalvo Road, Redwood City, CA 94062 (“GKOL”), and BeyondSpring Pharmaceuticals, Inc., a Delaware Corpo |
|
| April 30, 2020 |
Exhibit 4.23 Lan Huang, Ph.D. Chief Executive Officer BeyondSpring Pharmaceuticals, Inc. 28 Liberty Street, 39th Floor New York, NY 10005 Tel: 646.305.6387 January 1, 2020 RE: ANNUAL SALARY RAISE Edward Dongheng Liu Dear Edward, We are pleased to offer you an increase in your annual base salary from $300,000.00 to $430,000.00. In addition, we are increasing your annual bonus opportunity to 45% of |
|
| March 11, 2020 |
Exhibit 99.1 BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19 NEW YORK – March 11, 2020 – BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the submission of a provisional U.S. patent application |
|
| March 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by chec |
|
| February 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G10830100 (CUSIP Number) DECEMBER 31, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r |
|
| February 7, 2020 |
2,202,080 Ordinary Shares BeyondSpring Inc. TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-224437 PROSPECTUS SUPPLEMENT (To Prospectus dated May 3, 2018) 2,202,080 Ordinary Shares BeyondSpring Inc. We have entered into an Open Market Sale AgreementSM, dated as of May 21, 2019, as amended on February 7, 2020, or the sales agreement, with Jefferies LLC, or Jefferies, relating to our ordinary shares offered |
|
| February 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2020 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by c |
|
| February 7, 2020 |
Exhibit 1.2 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM February 7, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment”) is entered into as of the date first written above by BeyondSpring Inc., a Cayman Islands exempted company (the “Company”), and Jefferies LLC (“Agent”), that are p |
|
| January 23, 2020 |
EXHIBIT 99.1 BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) - BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the appointments of Drs. Daniel Zabrows |
|
| January 23, 2020 |
BYSI / BeyondSpring Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2020 Commission File Number: 001-38024 BeyondSpring Inc. (Translation of registrant's name into English) 28 Liberty Street 39th Floor (Address of principal executive office) Indicate by |
|
| December 18, 2019 |
BYSI / BeyondSpring Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive off |
|
| December 18, 2019 |
Exhibit 99.1 BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia (“CIN”) in Q1 2020 Plinabulin’s Anti-Cancer and CIN Prevention Mechanism Published in Peer Reviewed Journals New York, December 18, 2019 – BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical c |
|
| October 29, 2019 |
BYSI / BeyondSpring Inc. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2019 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive office) Indicate by ch |
|
| October 29, 2019 |
BeyondSpring Inc. 1,851,852 Ordinary Shares (Par Value $0.0001 Per Share) UNDERWRITING AGREEMENT Exhibit 1.1 BeyondSpring Inc. 1,851,852 Ordinary Shares (Par Value $0.0001 Per Share) UNDERWRITING AGREEMENT October 25, 2019 JEFFERIES LLC WILLIAM BLAIR & COMPANY, L.L.C. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o WILLIAM BLAIR & COMPANY, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: Introductor |
|
| October 28, 2019 |
1,851,852 Ordinary Shares BeyondSpring Inc. TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-234193 PROSPECTUS SUPPLEMENT (To Prospectus dated October 21, 2019) 1,851,852 Ordinary Shares BeyondSpring Inc. We are offering 1,851,852 ordinary shares with an aggregate offering price of $25,000,002. Our ordinary shares are listed on the Nasdaq Capital Market under the symbol “BYSI.” The last reported sales pric |
|
| October 25, 2019 |
Subject to Completion Preliminary Prospectus Supplement dated October 24, 2019 TABLE OF CONTENTS The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| October 17, 2019 |
BYSI / BeyondSpring Inc. CORRESP - - BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 October 17, 2019 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Gregory Dundas Re: BeyondSpring Inc. Registration Statement on Form F-3 (File No. 333-234193) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amende |
|
| October 15, 2019 |
BYSI / BeyondSpring Inc. F-3 - - F-3 As filed with the Securities and Exchange Commission on October 15, 2019 Registration No. |
|
| September 18, 2019 |
Exhibit 99.1 BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results - To Submit New Drug Applications (“NDAs”) in China for Both Non-Small Cell Lung Cancer (“NSCLC”) and Chemotherapy-Induced Neutropenia (“CIN”) in Q1 2020 - - To Submit NDAs in the United States (“U.S.”) for Both NSCLC and CIN in 2020 - NEW YORK, September 18, 2019 – BeyondSpring Inc. (“BeyondSpring” or |
|
| September 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2019 Commission File Number: 001-38024 BeyondSpring Inc. BeyondSpring Inc. 28 Liberty Street, 39th Floor New York, New York 10005 (Address of principal executive offices) Indicate by |
|
| August 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BeyondSpring Inc. (Name of Issuer) Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G10830100 (CUSIP Number) july 19, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
